Scientists Engineer Hookworms for Medicine Delivery

Researchers have engineered hookworms to act as live drug factories capable of delivering therapeutic molecules for chronic diseases, as detailed in a study published in Nature Communications. Led by molecular geneticist Dr.

Makedonka Mitreva from the School of Medicine St. Louis, the project employs CRISPR gene-editing technology to modify the Ancylostoma ceylanicum hookworm species, enabling it to produce antibodies that neutralize tetrodotoxin, a potent neurotoxin found in pufferfish.

This innovative approach aims to eliminate the need for daily medication for conditions such as autoimmune diseases and obesity. The engineered hookworms can survive in the human intestine for years, releasing therapeutic proteins into the bloodstream without significant harm to the host.

The project has received funding from the U.S. Defense Advanced Research Projects Agency (DARPA) to develop countermeasures against potential biological weapons.

While the research is in its early stages, it represents a crucial milestone in the development of live medicines for continuous treatment within the body.